Featured Post from ChristianaCare

ChristianaCare and The Wistar Institute advance partnership with new cancer research strategies

Mar 16, 2022

4 min

ChristianaCare’s Helen F. Graham Cancer Center & Research Institute is advancing its historic partnership with the Ellen and Ronald Caplan Cancer Center of The Wistar Institute in Philadelphia with three new research projects under way.


The new research projects consist of a population health study targeting triple negative breast cancer. Other projects focus on a new therapeutic target for epithelial ovarian cancer, the most lethal gynecologic cancer in the developed world, and the development of “mini organs” derived from stem cells.


Targeting triple negative breast cancer

Delaware has one of the highest incidence rates of triple-negative breast cancer in the United States. This highly aggressive cancer has few treatment options, because the cells test negative for three known treatment targets – estrogen, progesterone and HER2 protein receptors.


Working with patient data from the Graham Cancer Center, researchers are investigating potential contributing factors such as diet, alcohol use and genetic variants among women, and the effects of these on cancer metabolism. The team will also examine spatial relationships between cancer “hot spots”—geographic areas with a higher-than-expected prevalence—and modifiable risk factors.


Key resources for the study are blood and tissue samples from the Graham Cancer Center’s Tissue Procurement Center and its statewide High-Risk Family Cancer Registry.


The research team will be led by Director of Population Health Research at ChristianaCare Scott Siegel, Ph.D., and Lead Research Scientist Jennifer Sims Mourtada, Ph.D., at the Graham Cancer Center’s Cawley Center for Translational Cancer Research (CTCR). They will join Zachary Schug, Ph.D., at Wistar’s Molecular and Cellular Oncogenesis Program.


Researching novel therapy for ovarian cancer

The latest study supported by the Graham Cancer Center’s Tissue Procurement Program targets KAT6A expression as a novel therapy for ovarian cancer caused by a specific genetic mutation, called PP2R1A.


Epithelial ovarian cancer is the most common form of ovarian cancer and the leading cause of gynecologic cancer deaths in the United States. Chemoresistance to currently available platinum-based drugs like cisplatin represents a major treatment challenge, as more than 50 percent of affected women ultimately relapse and die from this disease.


Wistar’s Rugang Zhang, Ph.D., leader of the Immunology, Microenvironment and Metastases Program, is focused on developing novel therapeutics for subtypes of ovarian cancer that currently have no effective therapies and on improving the current standard of care. Dr. Zhang’s previous work suggests that KAT6A signaling plays a critical role in ovarian cancer progression. Targeting this signaling pathway could be an effective strategy for treating ovarian cancer.


Working with Dr. Zhang on this project are Graham Cancer Center gynecologic oncologists Mark Cadungog, M.D., director of Robotic Surgery, and Sudeshna Chatterjee-Paer, M.D., and Cawley CTCR’s Stephanie Jean, M.D., director of Gynecologic Oncology Research. Also collaborating with the team is Wistar’s Alessandro Gardini, Ph.D., assistant professor in the Gene Expression & Regulation Program.


‘Mini organs’ offer hope for therapeutics

Dr. Sims-Mourtada at the Cawley CTCR will lead a new program to culture organ-specific tissue from stem cells that could change the way diseases are studied and treated.


These so called “mini organs” or “organoids” are three-dimensional tissue cultures grown in the lab that replicate the complexity and functions of a specific tissue or organ found in the body. Organoids offer scientists a better model for how drugs and other therapeutics might interact with a patient’s particular type of tumor, opening new avenues for precision medicine.


“The ability to grow each patient’s tumor in a three-dimensional organoid along with our capability to create patient-derived xenograft or animal models as part of our PDX core, will allow us to fully capture the effects of genetic as well as gene altering behavioral and environmental influences that are lacking in current research models,” said Dr. Sims-Mourtada. “Our collaboration with Wistar to build these programs raises our clinical platform to the next level for studying new cancer biomarkers and treatments.”


Advancing a Pioneering Partnership

The Graham Cancer Center made history when it signed a first-of-its-kind agreement in 2011 with The Wistar Institute, pairing a National Cancer Institute, NCI-designated basic research institution with a community cancer center that is also an NCI Community Oncology Research Program (NCORP).


“Our partnership with Wistar has attracted national recognition as a model of collaboration that leverages cutting-edge research to benefit cancer prevention and therapy statewide,” says Nicholas J. Petrelli, M.D., Bank of America endowed medical director of ChristianaCare’s Helen F. Graham Cancer Center and Research Institute. “With Wistar, our productive collaborations over the last decade continue to drive discovery research toward clinical trials to benefit patients here at the Graham Cancer Center and in communities everywhere.”


“The Graham Center has been an ideal partner in our mission,” said Dario C. Altieri, M.D., Wistar president and CEO and director of the Ellen and Ronald Caplan Cancer Center. “Our scientists at Wistar have access to clinically-annotated primary patient specimens of the highest quality. As the majority of patients at the Graham Cancer Center are treatment naïve, this collaboration affords an opportunity to conduct unique, high impact mechanistic and correlative studies that will ultimately advance important scientific discoveries that hopefully will lead to better cancer therapies.”

You might also like...

Check out some other posts from ChristianaCare

1 min

ChristianaCare Nurses Inducted as American Academy of Nursing Fellows

In recognition of their extraordinary impact on the nursing profession, two ChristianaCare nurses have been named as Fellows of the American Academy of Nursing (AAN). This prestigious recognition highlights their significant contributions to nursing leadership, innovation and health care policy. Michelle Collins, DNP, APRN, CNS, ACNS-BC, NPD-BC, NEA-BC, LSSBB, currently serves as vice president of Nursing Professional Excellence at ChristianaCare. Throughout her accomplished 30-year career, Collins has played a crucial role in improving how nurses practice and learn. Her leadership was significant in achieving ChristianaCare’s third Magnet® designation, highlighting her commitment to excellence. Collins’ initiatives, including pioneering a Virtual Acute Care Nursing model and securing a $1.5 million grant for nursing technology integration, have set new standards in health care innovation. Danielle Sarik, Ph.D., APRN, CPNP-PC, is a nurse scientist consultant at ChristianaCare. Her research contributions have been integral in shaping policies that improve health care outcomes for children and families. Sarik is renowned for developing and implementing the Baby Steps model, recognized by the AAN as an Edge Runner designee. This pioneering transition of care approach addresses health equity for neonatal patients and families following discharge from the neonatal intensive care unit. “Induction into the Academy represents the highest honor in nursing,” said AAN President Linda Scott. “Earning the Fellow of the American Academy of Nursing (FAAN) credential is a significant recognition of one’s accomplishments and signifies the future impact they will make in collaboration with their colleagues in the Academy.”

3 min

‘You Can Do and Be Anything Coming From an HBCU’

A late July dinner was the finale to her second internship with ChristianaCare for Tania Paden. Her eight weeks at Christiana Hospital had left her feeling more confident in herself and excited to continue exploring direct patient care as she prepares to head back to Delaware State University in the fall. “I learned how to be more comfortable with direct patient care and communicate with the patients,” Paden said. “My favorite thing would have to be going to tour the different units and getting shadowing experiences throughout the hospital.” Paden is one of 10 Future of Health Scholarship Program recipients at ChristianaCare. Graduates from Delaware high schools attending Historically Black Colleges and Universities (HBCUs) were each awarded a $12,500 annual scholarship and a paid summer internship in 2021 each year until they graduate. The program, a partnership between ChristianaCare and the HBCU Week Foundation, is designed to help support HBCU students as they pursue degrees in health care. Teachable moments and big opportunities Paden’s enthusiasm is shared by Natalie Torres, director of Inclusion & Diversity at ChristianaCare, who oversees the scholarship program. “This experience is so much more than offering the scholarship funding,” Torres said. “It’s the time, it’s those quiet moments in-between meetings and their experiences where the teachable moments really take place. “When they come to us, we really want to lock into their lived experiences, and not only make sure they can thrive at ChristianaCare, but in life.” With these scholarships and other community-based endeavors, ChristianaCare continues to work to build a diverse workforce and represent its communities. Forbes recently listed ChristianaCare as one of America’s Best Employers for Diversity for the fourth year in a row. Although she is a young intern herself, Aniyah Barnett, a rising biochemistry junior at Hampton University, jumped at the chance to help make new caregivers feel comfortable at ChristianaCare. She played a key role welcoming medical and dental residents to campus. “My favorite project was probably the new resident orientation,” Barnett said. “I spent time getting all the new residents together, making sure they have all the information they need, and getting to meet them!” A pathway to medicine For Ashley Christopher, Esq., founder and CEO of HBCU Week Foundation, these scholarships mean a lot. Ten years ago, Christopher had a stroke that left her feeling scared and alone as she lay in hospital. Her cardiologist, a Black woman, was the only one who made her feel heard, she told the students during their summer-end dinner. With IT experiences gained at ChristianaCare, Future of Health scholar Solomon Devard is thinking about continuing on that path to become a system administrator for a big corporation. “She was the only one who made me feel safe, secure and seen during a time where I was questioning life as I knew it,” Christopher said. “You can do and be anything coming from an HBCU. This scholarship gives students who want to go to HBCUs a pathway to the field of medicine for more people who look like me to tend to the care of patients.” The HBCU Week Foundation creates opportunities through coaching and scholarships for students who want to attend HBCUs. To support these efforts, ChristianaCare committed $500,000 to providing financial and networking support, and hands-on experiences for HBCU students. “These students are energized, they’re talented, and I’m so excited for the next step,” Christopher said. “I just feel so happy to be a part of that process.”

2 min

Center for Heart & Vascular Health Recognized for Continued Excellence with American College of Cardiology HeartCARE Center Designation

For the fifth consecutive year, ChristianaCare’s Center for Heart & Vascular Health has earned the premier recognition from The American College of Cardiology (ACC) – the HeartCARE Center National Distinction of Excellence award – for its commitment to comprehensive, high quality cardiovascular care. ChristianaCare was the first hospital system in Delaware and one of only a handful in the U.S. to attain this recognition when it was first awarded in 2020 from the ACC, a nonprofit medical association representing more than 50,000 cardiovascular specialists. “We are proud to be a regional leader for cardiovascular care with the most advanced medical, surgical and minimally invasive specialty care, technology and research,” said Kirk Garratt, M.D., medical director of ChristianaCare’s Center for Heart & Vascular Health. “Congratulations to our entire team and all who collaborate seamlessly to deliver care 24/7. As a result, those living in Delaware and neighboring states can receive the highest quality cardiovascular care from the Center for Heart & Vascular Health.” Hospitals that have earned an ACC HeartCARE Center designation have met a set of criteria, including participating in at least two ACC accreditation services programs, national cardiovascular data registries and targeted quality improvement campaigns designed to close gaps in guideline-based care. In addition to being a current recipient of the HeartCARE Center designation, ChristianaCare participates in the ACC’s chest pain MI with PCI (heart attack with angioplasty) and resuscitation accreditation, cath lab accreditation and the Society of Thoracic Surgeon database. “ChristianaCare has demonstrated its commitment to providing the community with excellent heart care,” said Deepak L. Bhatt, M.D., MPH, FACC, chair of the ACC accreditation management board. “ACC accreditation services is proud to award the Center for Heart & Vascular Health with the HeartCARE Center designation.” Hospitals receiving the HeartCARE Center designation have demonstrated their commitment to consistent, high-quality cardiovascular care through comprehensive process improvement, disease and procedure-specific accreditation, professional excellence and community engagement. ChristianaCare has proven to be a forward-thinking institution with goals to advance the cause of sustainable quality improvement. The Center for Heart & Vascular Health is among the largest, most capable regional heart centers on the East Coast. It is among the few centers in the region that integrates cardiac surgery, vascular surgery, vascular interventional radiology, cardiology and interventional nephrology in a single location. Its expert clinical staff performed nearly 200,000 patient procedures last year.

View all posts
Powered by